In 1944 Heilman1 demonstrated the sensitivity of Pasteurella tularensis to streptomycin under experimental conditions, and fifteen months later its clinical use in tularemia was reported by Foshay and Pasternack,2 who noted the rapid regression of symptoms in 7 patients with ulceroglandular tularemia. Pulaski and Amspacher3 reported successful treatment with streptomycin in 10 cases which occurred in United States Army hospitals, and Hunt4 reported 12 cases of pleuropulmonary involvement in which streptomycin therapy was. used, with prompt recovery in all except 1 case, in which, death was attributed to pulmonary embolus. Seven cases of laboratory-acquired infection, successfully treated by' streptomycin, were presented by Howe.5 The National Research Council reported the treatment of 67 patients with 63 recoveries.
Before streptomycin became available, 27 patients with tularemia were seen at this hospital, and subsequently 27 patients have been treated with streptomycin. The purpose of this paper is to